Clinical Trial: A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N

Brief Summary: The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 until a decision regarding reimbursement in France is effective for canakinumab (Ilaris®) in these indications.

Detailed Summary:
Sponsor: Novartis Pharmaceuticals

Current Primary Outcome: adverse events [ Time Frame: every 4 weeks up to 1 year ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Novartis

Dates:
Date Received: December 23, 2014
Date Started: November 3, 2014
Date Completion: December 22, 2018
Last Updated: April 5, 2017
Last Verified: April 2017